Skip to content

The use of perianal methylene blue injection on post-haemorrhoidectomy pain

A single centre prospective randomised clinical trial of the use of perianal methylene blue injection on post-haemorrhoidectomy pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN69637260
Enrollment
80
Registered
2011-07-11
Start date
2008-08-27
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic 3rd and 4th degree haemorrhoids Circulatory System Haemorrhoids

Interventions

Patients will be randomised to undergo haemorrhoidectomy with methylene blue and marcaine 0.5% or marcaine 0.5% only alone intradermal injections using sealed envelopes. A standard medication package

Sponsors

Khoo Teck Puat Hospital (Singapore)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Fresh cases of symptomatic 3rd and 4th degree haemorrhoids 2. Aged between 21 and 80 years of age 3. Able to give informed consent

Exclusion criteria

Exclusion criteria: 1. Undergoing combined procedures for fissures or fistulae 2. Do not give informed consent 3. Allergy reactions to diclofenac, Daflon®, Fybogel®, methylene blue, paracetamol 4. Pregnant or breast feeding women

Design outcomes

Primary

MeasureTime frame
1. Pain, assessed using a 11-point visual analogue pain score from 0 to 10 (0 = no pain; 10 = unbearable pain). Participants will be asked to record their maximum pain score daily before retiring. 2. Total number of analgesics tablets patients have taken for the day

Secondary

MeasureTime frame
Complications which include: 1. Pain requiring unscheduled stay or unscheduled return 2. Urinary retention 3. Delayed bleeding 4. Discharge 5. Itching 6. Skin reaction to methylene blue

Countries

Singapore

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026